ReviewFrontiers in immunology2022
Research progress on the pathogenesis of Graves' ophthalmopathy: Based on immunity, noncoding RNA and exosomes.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- RNA modifications as innovative pharmaceutical targets: emerging drug delivery strategies and precision therapeutics for cancer immunotherapy and metabolic diseases.Molecular biology reports · 2026Review
- Unilateral proptosis as the manifestation of euthyroid Graves orbitopathy: A case report.Medicine · 2026Article
- Linc01748 regulates the prognosis and related mechanisms of gastric cancer by targeting miR-130a-5p.Hereditas · 2026Article
- Extracellular vesicles in Graves' disease and Graves' orbitopathy: immunoregulatory mechanisms, biomarkers, and therapeutic potentials.Frontiers in immunology · 2026Review
- Effect of enalapril and losartan on the expression of genes involved in inflammation, fibrogenesis, and apoptosis in orbital fibroblasts of graves' ophthalmopathy.BMC research notes · 2025Article
- Machine learning unveils hypoxia-immune gene hub for clinical stratification of thyroid-associated ophthalmopathy.Scientific reports · 2025Article
- Inflammatory Proteins Mediate the Effect of Gut Microbiota on Graves' Ophthalmopathy: A Mendelian Randomization Study.Translational vision science & technology · 2025Article
- Current concepts of tocilizumab efficacy in active moderate-to-severe corticosteroid-resistant cases of Graves' orbitopathy.Frontiers in endocrinology · 2025Review
- Correlation between intraorbital structural alterations and diplopia in thyroid-associated ophthalmopathy: an MRI-based study.American journal of translational research · 2025Article
- Identification of key extracellular proteins as the potential biomarkers in thyroid eye disease.PloS one · 2025Article
- Development and validation of a nomogram prediction model for factors influencingFrontiers in endocrinology · 2025Article
- Correlation between extraocular muscle enlargement and thyroid autoantibodies in thyroid eye disease.Japanese journal of ophthalmology · 2024Article
- The Role of Fibrogenesis and Extracellular Matrix Proteins in the Pathogenesis of Graves' Ophthalmopathy.International journal of molecular sciences · 2024Review
- Impact of ibrutinib on inflammation in a mouse model of Graves' orbitopathy.Frontiers in endocrinology · 2024Article
- Thyroid-associated ophthalmopathy: the role of oxidative stress.Frontiers in endocrinology · 2024Review
- Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system.Frontiers in pharmacology · 2024Article
- Thyroid-associated ophthalmopathy and ferroptosis: a review of pathological mechanisms and therapeutic strategies.Frontiers in immunology · 2024Review
- Immunological Processes in the Orbit and Indications for Current and Potential Drug Targets.Journal of clinical medicine · 2023Review
- TSG6 Plays a Role in Improving Orbital Inflammatory Infiltration and Extracellular Matrix Accumulation in TAO Model Mice.Journal of inflammation research · 2023Article
- Thyroid hormones and minerals in immunocorrection of disorders in autoimmune thyroid diseases.Frontiers in endocrinology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graves' ophthalmopathy (GO), also known as thyroid-associated ophthalmopathy, is a common potentially vision-threatening organ-specific autoimmune disease and the most common extrathyroidal manifestation of Graves' disease. It can happen to those who have hyperthyroidism or euthyroidism. At present, the pathogenesis of GO has not been fully elucidated, and the majority of clinical treatments are symptomatic. Therefore, we are eager to discover any new therapeutic strategies that target the etiology of GO. To provide fresh ideas for the creation of new therapeutic techniques, this study primarily discusses the research state and progress of GO-related pathogenesis from the perspectives of GO's cellular immunity, autoantigens, non-coding RNAs, and exosomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.